Imgn632, A Cd123-Alkylating Adc Bearing A Dna-Alkylating Ign Payload, Combines Effectively With Azacitidine And Venetoclax In Vivo, Prolonging Survival In Preclinical Models Of Human Acute Myeloid Leukemia (Aml)

Introduction: IMGN632, a novel CD123-targeting ADC, demonstrates a favorable safety profile and complete remissions as a monotherapy in patients with relapsed/refractory AML and BPDCN (NCT03386513). We have previously reported the synergy of combining IMGN632 with venetoclax (BCL-2 inhibitor) (EHA, 2019, abstract #PF201). Given the recent approval of azacitidine (AZA, a hypomethylating agent) and venetoclax (VEN) in AML patients unfit for intensive chemotherapy, we investigated the combination of IMGN632 with AZA and the triple combination of IMGN632, AZA and VEN.